Clinical Trial Update: Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for sapanisertib in metastatic or unresectable pancreatic neuroendocrine tumors (PENET G1/G2; refractory), with completed status a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2 | Phase 2 | Status: COMPLETED | Results posted: 2022-04-05